^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

sutetinib (SZMD4)

i
Other names: SZMD4
Company:
Jiangsu Suzhong Pharma, Medolution, Teligene
Drug class:
EGFR inhibitor
Related drugs:
5ms
Phase classification • Metastases
|
EGFR (Epidermal growth factor receptor)
|
sutetinib (SZMD4)
8ms
PK/PD data • Journal
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
|
sutetinib (SZMD4)
9ms
A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC (clinicaltrials.gov)
P2, N=66, Recruiting, Teligene US | Trial completion date: Jun 2025 --> Sep 2025 | Trial primary completion date: Jun 2025 --> Sep 2025
Trial completion date • Trial primary completion date • Metastases
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
|
sutetinib (SZMD4)
11ms
Trial completion date • Trial initiation date • Trial primary completion date • Metastases
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
|
sutetinib (SZMD4)
1year
Enrollment open • Metastases
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
|
sutetinib (SZMD4)
over1year
New P2 trial • Metastases
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
|
sutetinib (SZMD4)
over1year
A phase 2a study evaluating the efficacy and safety of sutetinib in patients with advanced non–small-cell lung cancer (NSCLC) harboring uncommon EGFR mutations. (ASCO 2023)
Sutetinib demonstrated a high response rate with durable antitumor activity in patients with NSCLC harboring uncommon EGFR mutations. The toxicities are expected and comparable to other EGFR TKIs. A multi-center phase 2b study is ongoing in the United States and China to further evaluate Sutetinib in uncommon EGFR mutation NSCLC.
Clinical • P2a data • Metastases
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I
|
sutetinib (SZMD4)
over1year
Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer (clinicaltrials.gov)
P2b, N=99, Recruiting, Teligene US | Not yet recruiting --> Recruiting | Trial completion date: Mar 2024 --> Feb 2025 | Trial primary completion date: Feb 2023 --> Aug 2024
Enrollment open • Trial completion date • Trial primary completion date • Metastases
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR G719X + EGFR S768I
|
sutetinib (SZMD4)